Scott Hutton'un ücretlendirmesi Biodesix'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$44m
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$47m
Dec 31 2023	US$2m	US$515k	-US$52m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$3m	US$515k	-US$65m
Sep 30 2022	n/a	n/a	-US$58m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$5m	US$490k	-US$43m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$2m	US$364k	-US$31m
Sep 30 2020	n/a	n/a	-US$33m
Jun 30 2020	n/a	n/a	-US$34m
Mar 31 2020	n/a	n/a	-US$33m
Dec 31 2019	US$337k	US$298k	-US$31m

Tazminat ve Piyasa: Scott 'nin toplam tazminatı ($USD 2.29M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.41M ).

Tazminat ve Kazançlar: Scott 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Scott Hutton (52 yo)

5yrs

Görev süresi

US$2,290,546

Tazminat

Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Hutton	President	5yrs	US$2.29m	0.37% $ 554.3k
Robin Cowie	CFO, Secretary & Treasurer	7.8yrs	US$844.37k	0.14% $ 211.5k
Kieran O'Kane	Chief Commercial Officer	6.9yrs	US$672.62k	0.067% $ 101.3k
Heinrich Röder	Founder & CTO	no data	Veri yok	Veri yok
Jessica Olbricht	Senior Director of Human Resources	1yr	Veri yok	Veri yok
Gary Pestano	Chief Development Officer	6.3yrs	Veri yok	0.087% $ 132.1k
Bobbi Coffin	Chief Growth Officer	4.8yrs	Veri yok	Veri yok
James Jett	Co-Chief Medical Officer	no data	Veri yok	Veri yok
Steven Springmeyer	Co-Chief Medical Officer	4.7yrs	Veri yok	Veri yok
Christopher Vazquez	VP & Controller	3.9yrs	Veri yok	0.0080% $ 12.1k

4.9yrs

Ortalama Görev Süresi

49.5yo

Ortalama Yaş

Deneyimli Yönetim: BDSX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Hutton	President	5yrs	US$2.29m	0.37% $ 554.3k
John Patience	Independent Chairman	16.6yrs	US$187.58k	5.07% $ 7.7m
Jack Schuler	Independent Director	16.6yrs	US$187.58k	21.44% $ 32.4m
Hany Massarany	Independent Director	4.5yrs	US$201.47k	0.23% $ 350.6k
Lair Kennedy	Independent Director	2yrs	US$465.10k	17.5% $ 26.5m
Paul A. Bunn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Matthew Strobeck	Independent Director	13yrs	US$196.84k	2.1% $ 3.2m
John Kayyem	Independent Director	3.1yrs	US$187.58k	0.25% $ 371.8k
David Carbone	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Craig Whitehouse	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jean Franchi	Independent Director	4.8yrs	US$206.10k	0.056% $ 85.0k
Charles Watts	Independent Director	5.5yrs	US$187.58k	0.26% $ 390.0k

5.0yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BDSX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/31 08:46
Gün Sonu Hisse Fiyatı	2025/01/31 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Biodesix, Inc. 9 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Sung Ji Nam	BTIG
Kyle Mikson	Canaccord Genuity
William Bonello	Craig-Hallum Capital Group LLC

Biodesix Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Biodesix, Inc., Annual General Meeting, May 21, 2024

President notifies of intention to sell stock

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Independent Director recently bought US$125k worth of stock

Recent updates

The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%

Biodesix, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2024

With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Biodesix, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024-25

Biodesix, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Biodesix, Inc. to Report Q3, 2024 Results on Nov 01, 2024

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc. Raised Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Biodesix, Inc., Annual General Meeting, May 21, 2024

Biodesix, Inc. announced that it expects to receive $34.999422 million in funding

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $20.000607 million.

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

President notifies of intention to sell stock

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Consensus EPS estimates upgraded to US$0.68 loss

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Biodesix, Inc. Announces New Clinical Utility Evidence for the Nodify XL2 Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Director recently bought US$125k worth of stock

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix, Inc. Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors and Audit Committee of the Board, Effective January 3, 2023

Independent Director recently bought US$148k worth of stock

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Price target decreased to US$5.00

Biodesix, Inc. Presents New Data from the Insight Study At the 2022 Society for Immunotherapy of Cancer 37Th Annual Meeting

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Biodesix, Inc. to Report Q3, 2022 Results on Nov 03, 2022

A Second Look At Biodesix

Biodesix, Inc. Provides Revenue Guidance for the Third Quarter 2022

Biodesix expects Q3 revenue above the consensus

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Biodesix, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Biodesix, Inc.(NasdaqGM:BDSX) dropped from Russell 2000 Growth Index

Biodesix, Inc. Obtains Medicare Coverage for the Nodify CDT Lung Nodule Test

Biodesix: Bad Diagnosis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2022